Leoclan Co Ltd

Leoclan maintains a strong liquidity position with cash and equivalents of ¥4.78 billion, representing 44% of total assets, and a current ratio of 2.23, well above the industry median. The company's liquidity_fpt score of 0.94 indicates robust short-term financial flexibility. Profitability metrics show a return on equity of 2.71% and return on assets of 1.41%, both below the industry median for medical equipment and services. Operating income of ¥288 million reflects a 1.34% margin, which is in line with the sector average but leaves room for improvement in cost management. The company's revenue is distributed across three segments: Medical Total Solution (72%), Remote Image Diagnosis Service (20%), and Provide Lunch (8%). Domestic operations account for 98% of total revenue, with no material international exposure reported in the latest financials. Outlook for FY2024 shows a 5.2% revenue increase to ¥22.6 billion, driven by expansion in the Remote Image Diagnosis Service segment. Operating income is projected to grow by 3.8% to ¥299 million, supported by higher utilization of existing infrastructure. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. No dilution sources were identified in the latest filings. Recent 10-K filings highlight ongoing investments in digital health infrastructure and a 10% increase in R&D spending in FY2023. The company also announced a partnership with a regional hospital chain to expand its remote diagnosis services.